What to know about new diagnostic tools, targeted medications, and other recent advances in the treatment of metastatic NSCLC ...

An expert discusses a treatment approach for the patient case above, how factors like brain metastases influence first-line treatment choices, reviews high-risk/CNS outcomes data from MARIPOSA and ...

An expert discusses treatment goals for patients with EGFR-mutated advanced/metastatic NSCLC, how to approach combination therapy with high-risk patients, and how recent data has influenced their ...

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

Results from three trials continue to demonstrate the potential of DATROWAY® (datopotamab deruxtecan) in combination with ...

These findings support the need for a phase III randomized controlled trial to definitively determine whether the addition of an antiangiogenic to a second or even a third-generation TKI provides ...

The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements ...

The leading PD-1+ NSCLC Companies such as Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma and others. Promising PD-1+ ...

Bristol Myers Squibb (BMS) has announced that its PD-1 immune checkpoint inhibitor Opdivo (nivolumab) has been approved by ...

UK MHRA approves SFL Pharmaceuticals’ aumolertinib to treat non-small cell lung cancer: United Kingdom Wednesday, June 4, 2025, 11:00 Hrs [IST] The Medicines and Healthcare prod ...